TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA for MCL. However, development of relapses to BA is recognized with poor patient outcomes. Multiple CAR T-cell therapies have been approved for other lymphomas and the resistance mechanisms have been investigated. However, the mechanisms underlying BA relapse in MCL have not been investigated and whether any previously reported resistance mechanisms apply to BA-relapsed patients with MCL is unknown.

Methods

To interrogate BA resistance mechanisms in MCL, we performed single-cell RNA sequencing on 39 longitudinally collected samples from 15 BA-treated patients

SUBMITTER: Jiang VC 

PROVIDER: S-EPMC9513944 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature